The effects of selective antagonist of serotonin 5-HT 2C receptor SB242084 on rat's locomotion in animal models of psychoses;Účinky selektivního antagonisty serotoninového 5-HT 2C receptoru SB242084 na lokomoci potkana v animá lních modelech psychóz

Psychiatrie

Volumn 10, Issue SUPPL. 3, 2006, Pages 16-20

  Páleníček, Tomáš ^a   Bubeníková Valešová, Věra ^a   Horáček, Jiří ^a   Vrajová, Monika ^a   Novák, Tomáš ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Locomotion; LSD (N,N diethyllysergamide); MK 801 (dizocilpin); Psilocin (4 hydroxy N,N dimethyltryptamine); Rats; SB 242084; Serotonin

Indexed keywords

EID: 84864500147     PISSN: 12117579     EISSN: 12126845     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M: Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995;34:1635-1645.
2. Adams B, Moghaddam B: Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 1998;18:5545-5554. (Pubitemid 28311969)
3. Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, Sandberg M: Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 1999;290:1393-1408. (Pubitemid 29400285)
4. Arnt J, Skarsfeldt T: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101. (Pubitemid 28026679)
5. Bankson MG, Cunningham KA: 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 2001;297:846-852. (Pubitemid 32472478)
6. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152. (Pubitemid 29292403)
7. Bexis S, Docherty JR: Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors. Br J Pharmacol 2006;147:926-934.
8. Bishop C, Daut GS, Walker PD: Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology 2005;49:350-358. (Pubitemid 41112822)
9. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE: Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 2000;43:4701-4710.
10. Breese GR, Knapp DJ, Moy SS: Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 2002;26:441-455. (Pubitemid 36158662)
11. Bromidge SM, Duckworth M, Forbes IT, Ham P, King FD, Thewlis KM, Blaney FE, Naylor CB, Blackburn TP, Kennett GA, Wood MD, Clarke SE: 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist. J Med Chem 1997;40:3494-3496. (Pubitemid 27465078)
12. Bubenikova V, Horacek J, Kozeny J, Platilova V, Zavesicka L, Palenicek T, Hoschl C: The effect of tryptophan depletion on the action of haloperidol in MK-801-treated rats. Eur J Pharmacol 2004;502:109-116. (Pubitemid 39311371)
13. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96. (Pubitemid 26053226)
14. Carey RJ, DePalma G, Damianopoulos E, Muller CP, Huston JP: The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berl) 2004;177:46-54. (Pubitemid 40109913)
15. Carlsson ML, Carlsson A, Nilsson M: Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004;11:267-277. (Pubitemid 38240207)
16. Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, Waters N: The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm 1999;106:123-129. (Pubitemid 29137509)
17. Chen NH, Reith ME: Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-npropylamino) tetralin. J Neurochem 1995;64:1585-1597.
18. Dall'Olio R, Gaggi R, Bonfante V, Gandolfi O: The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol 1999;10:63-71. (Pubitemid 29106289)
19. Dalton GL, Lee MD, Kennett GA, Dourish CT, Clifton PG: mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes. Neuropharmacology 2004;46:663-671. (Pubitemid 38292971)
20. Di M, V, Di GG, Di MM, Esposito E: SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999;38:1195-1205. (Pubitemid 29292408)
21. Dourish CT, Hutson PH, Curzon G: Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology (Berl) 1985;86:197-204. (Pubitemid 15077754)
22. Geyer MA, Light RK: LSD-induced alterations of investigatory responding in rats. Psychopharmacology (Berl) 1979a;65:41-47. (Pubitemid 10222235)
23. Geyer MA, Light RK, Rose GJ, Petersen LR, Horwitt DD, Adams LM, Hawkins RL: A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl) 1979b;65:35-40. (Pubitemid 10222234)
24. Horacek J.: Neurobiologie pùsobení halucinogenních látek (Neurobiology of hallucinogens). Adiktologie 2005;5:134-150.
25. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409. (Pubitemid 43763739)
26. Ireland MD, Lowe AS, Reavill C, James MF, Leslie RA, Williams SC: Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging. Neuroscience 2005;133:315-326. (Pubitemid 40694180)
27. Jackson DM, Johansson C, Lindgren LM, Bengtsson A: Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 1994;48:465-471. (Pubitemid 24197367)
28. Jentsch JD, Roth RH: The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201-225. (Pubitemid 29067401)
29. Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T: The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol Biochem Behav 1998;59:1003-1009. (Pubitemid 28237916)
30. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP: SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997;36:609-620. (Pubitemid 27272106)
31. Khroyan TV, Baker DA, Fuchs RA, Manders N, Neisewander JL: Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference. Psychopharmacology (Berl) 1998;139:332-341. (Pubitemid 28435030)
32. Kleven MS, Koek W: Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon. J Pharmacol Exp Ther 1996;276:388-397.
33. Krebs-Thomson K, Lehmann-Masten V, Naiem S, Paulus MP, Geyer MA: Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin. Eur J Pharmacol 1998a;343:135-143. (Pubitemid 28138595)
34. Krebs-Thomson K, Paulus MP, Geyer MA: Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 1998b;18:339-351. (Pubitemid 28140659)
35. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr., Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214. (Pubitemid 24081509)
36. Krystal JH, Perry EB, Jr., Gueorguieva R, Belger A, Madonick SH, bi-Dargham A, Cooper TB, Macdougall L, bi-Saab W, D'Souza DC: Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005;62:985-994.
37. Lejeune F, Millan MJ: Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors. Eur J Neurosci 2000;12:3265-3275.
38. Leysen JE: 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:11-26.
39. Lindquist MP, Gotestam KG: Open-field behavior after intravenous amphetamine analogues in rats. Psychopharmacology (Berl) 1977;55:129-133. (Pubitemid 8243240)
40. Marona-Lewicka D, Nichols DE: Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol 1994;258:1-13. (Pubitemid 24174979)
41. Martin P, Carlsson ML, Hjorth S: Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 1998a;9:2985-2988. (Pubitemid 28555632)
42. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML: Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone. J Neural Transm 1998b;105:365-396. (Pubitemid 28365023)
43. Mazzola-Pomietto P, Aulakh CS, Wozniak KM, Murphy DL: Evidence that mchlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors. Psychopharmacology (Berl) 1996;123:333-339.
44. Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M: The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 2004;174:341-357. (Pubitemid 39044292)
45. Nichols DE: Hallucinogens. Pharmacol Ther 2004;101:131-181. (Pubitemid 38167565)
46. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM: Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N- diethyllysergamide (LSD). J Med Chem 2002;45:4344-4349. (Pubitemid 35025580)
47. Ninan I, Kulkarni SK: 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur J Pharmacol 1998;358:111-116. (Pubitemid 28458882)
48. O'Neill MF, Hicks CA, Shaw G, Parameswaran T, Cardwell GP, O'Neill MJ: Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. J Pharmacol Exp Ther 1998;287:839-846. (Pubitemid 29131590)
49. Ouagazzal AM, Creese I: Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol Biochem Behav 2000;67:637-645. (Pubitemid 32103576)
50. Palenicek T, Bubenikova V., Votava M., Horacek J.: Účinky MDMA, LSD a psilocinu na lokomoci potkana (The effects of MDMA, LSD and Psilocin on locomotion of the rat). Adiktologie 2005;5:120-130.
51. Palenicek T, Votava M, Bubenikova V, Horacek J: Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 2005;86:546-553. (Pubitemid 41586251)
52. Passie T, Seifert J, Schneider U, Emrich HM: The pharmacology of psilocybin. Addict Biol 2002;7:357-364. (Pubitemid 35402507)
53. Paulus MP, Geyer MA: The effects of MDMA and other methylenedioxy- substituted phenylalkylamines on the structure of rat locomotor activity. Neuropsychopharmacology 1992;7:15-31.
54. Smith JA, Boyer-Millar C, Goudie AJ: Does MK-801 discrimination constitute an animal model of schizophrenia useful for detecting atypical antipsychotics? Pharmacol Biochem Behav 1999;64:429-433. (Pubitemid 29438634)
55. Steinpreis RE, Salamone JD: The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Res 1993;612:263-270. (Pubitemid 23167290)
56. Szabo ST, Blier P: Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse 2001;42:203-212. (Pubitemid 33027294)
57. Vollenweider FX: Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 1998;31 Suppl 2:92-103. (Pubitemid 28396278)
58. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J: Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res 1998a;83:149-162. (Pubitemid 28522506)
59. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D: Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998b;9:3897-3902. (Pubitemid 29189323)
60. Wedzony K, Mackowiak M, Zajaczkowski W, Fijal K, Chocyk A, Czyrak A: WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 2000;23:547-559.